Rimonabant Meta-Analysis Reveals Increased Risk Of Psychiatric Events – The Lancet
This article was originally published in The Pink Sheet Daily
Executive Summary
Study introduces nothing new about the obesity drug that has not been discussed with regulatory authorities, Sanofi-Aventis responds to “The Pink Sheet” DAILY.
You may also be interested in...
UK’s NICE Proposes Coverage For Troubled Sanofi Obesity Drug Rimonabant
British agency recommends CB-1 receptor antagonist as adjunct to diet and exercise for obese adults intolerant of Xenical, Meridia.
UK’s NICE Proposes Coverage For Troubled Sanofi Obesity Drug Rimonabant
British agency recommends CB-1 receptor antagonist as adjunct to diet and exercise for obese adults intolerant of Xenical, Meridia.
FDA Issues Suicidality Alert On Antiepileptics
A class-wide relabeling is expected, but Pfizer says that Neurontin and Lyrica show no signs of increased events.